Systemic Sclerosis

 

Stem Cell Treatment Improves Quality of Life in Systemic Sclerosis

September 28, 2020

Autologous hematopoietic stem cell transplants (AHSCT) improve the quality of life in patients with systemic sclerosis (SSc), researchers say.

Ninfetanib Improves and Stabilizes Lung Function in Systemic Sclerosis

November 18, 2019

Patients who have systemic sclerosis-associated interstitial lung disease and received nintedanib were more likely to have improved lung function than patients who received a placebo, according to a new study. Not only did nintedanib improve forced vital capacity, but patients who received the drug were less likely to experience declining clinical status and more likely to see their conditions stabilize.

Riociguat for Systemic Sclerosis Digital Ulcers May Require Longer Treatment

September 12, 2019

A proof of concept clinical trial for riociguat (Adempas, Bayer) for patients with systemic sclerosis indicates that longer treatment periods may be necessary to heal digital ulcers. In this trial, the treatment wasn't effective in reducing the number of digital ulcers.

Systemic Sclerosis Treatment may Heighten Risk Factors

July 28, 2019

ACE inhibitors appear to heighten the risk of scleroderma renal crisis (SRC), a potentialy deadly complication in patients with systemic sclerosis.

Nintedanib Shows Efficacy for Systemic Sclerosis Lung Disease

June 10, 2019

Patients with systemic sclerosis-associated interstitial lung disease who also take nintedanib experience a lower drop in their forced vital capacity, according to a new study.

Scleroderma: A Primary Care Approach

January 24, 2019

The focus here: early signs and symptoms that can point to the diagnosis.

Synthetic Cannabinoid Shows Promise for Rare Subtype of Systemic Sclerosis

June 22, 2018

A potential non-immunosuppressive treatment option for patients with diffuse cutaneous systemic sclerosis.

Rheumatology News for Primary Care

February 01, 2018

Highlights of 5 topline news stories from the FDA, CDC, and American College of Rheumatology-with real-world implications for primary care practice.

Shock-Waves Reduce Finger Ulcers in Scleroderma

November 22, 2017

Compared with conventional treatment, extracorporeal shock-wave therapy resulted in a significant decrease in finger ulcers.

Systemic Sclerosis Linked With Altered Gut Microbiome

July 24, 2017

Low Bacteroidetes levels may suggest higher disease activity as in Crohn and other inflammatory diseases.

Steroids Pose Infection Risk During Pregnancy

April 24, 2017

Research shows that for women with autoimmune disease, the increase risk of infection during pregnancy is associated with steroids, not DMARDs.

Early Treatment of Systemic Sclerosis Symptoms Leads to Better Outcomes

November 29, 2016

Good early management of pulmonary hypertension in patients with systemic sclerosis leads to better outcomes and fewer complications, researchers report.

Outcomes: Systemic Sclerosis Patients with Pulmonary Hypertension

November 28, 2016

Systemic sclerosis patients with pulmonary hypertension and heart dysfunction are more likely to succumb from scleroderma-related causes, researchers report.

Treating Primary and Secondary Raynaud’s

October 07, 2016

In this slideshow, we summarize the difference between primary and secondary Raynaud’s phenomenon and recommended treatments.

How much do you know about Raynaud’s phenomenon?

October 05, 2016

The onset of Raynaud's phenomenon at 40 years could predict whether a connective tissue disease will develop.

Phase II Tocilizumab Trial Shows Little Benefit for Systemic Sclerosis

May 31, 2016

The next Rheumatology Journal Club Twitter chat will be from 4-5 p.m. and 10-11 p.m. EST, June 2. The chat will focus on tocilizumab for systemic sclerosis.

Mycophenolate or Cyclophosphamide for Lung Disease?

January 06, 2016

Lung scarring early in systemic scleroderma can reduce lung function and leave patients gasping for breath. New treatments show promise.

Two Drugs Slow Lung Scarring in Systemic Sclerosis

November 08, 2015

Patients with systemic sclerosis who take cyclophosphamide or mycophenolate mofitil experience a decrease in lung scarring.

The Annual Review: Systemic Sclerosis Research

September 23, 2015

A Clinical and Experimental Rheumatology review offers a critical analysis of recent studies on systemic sclerosis to best classify and manage this chronic condition.

Dangerous Clot Risks Higher in SSc

July 27, 2015

Patients diagnosed with systemic sclerosis (SSc) may have a three times greater risk of venous thromboembolism (VTE) – including potentially deadly clots in the lungs – and an increased risk in the first year after a diagnosis.